Table 1.
Baseline characteristics
| Characteristic | Placebo (n=50) | Atrasentan 0.75 mg/d (n=78) | Atrasentan 1.25 mg/d (n=83) |
|---|---|---|---|
| Age, y | 64.3±9.0 | 65.0±9.8 | 64.5±8.8 |
| Sex | |||
| Male | 40 (80) | 63 (81) | 57 (69) |
| Female | 10 (20) | 15 (19) | 26 (31) |
| SBP, mmHg | 136±14 | 138±14 | 136±15 |
| DBP, mmHg | 72±10 | 75±10 | 74±9 |
| eGFR, ml/min per 1.73 m2 | 49.3±13.3 | 47.9±14.6 | 50.6±13.6 |
| HbA1c, % | 7.4±1.3 | 7.5±1.5 | 7.7±1.4 |
| Weight, kg | 84.3±20.2 | 87.1±22.1 | 88.3±18.4 |
| Hemoglobin, g/dl | 12.7±1.8 | 12.9±1.5 | 12.9±1.8 |
| Hematocrit, % | 38.1±5.4 | 38.8±4.3 | 38.6±5.3 |
| Serum albumin, g/dl | 4.0±0.4 | 4.0±0.4 | 4.1±0.3 |
| BNP, median (Q1–Q3), pg/ml | 31.7 (18.3–93.0) | 33.0 (16.0–70.0) | 33.5 (14.0–64.0) |
| UACR, median (Q1–Q3), mg/g creatinine | 671 (410–1536) | 878 (515–1682) | 826 (481–1389) |
| RAS inhibitors | 50 (100) | 78 (100) | 83 (100) |
| Diuretics | |||
| Loop diuretics | 19 (38) | 29 (37) | 27 (33) |
| Thiazides | 29 (58) | 42 (54) | 43 (52) |
Values are mean±SD, n (%), or as otherwise indicated. SBP, systolic BP; DBP, diastolic BP; HbA1c, glycated hemoglobin; BNP, B-type natriuretic peptide; Q1, quartile 1; Q3, quartile 3; UACR, urinary albumin to creatinine ratio; RAS, renin-angiotensin system. Modified from reference 5, with permission.